Journal of Vaccine Research 2024, Vol.14, No.4, 196-206 http://medscipublisher.com/index.php/jvr 204 Acknowledgments Thank you to the anonymous peer reviewers for their suggestions on improving the initial draft of this manuscript. Conflict of Interest Disclosure The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Andersson N., Thiesson E., Baum U., Pihlström N., Starrfelt J., Faksová K., Poukka E., Lund L., Hansen C., Aakjær M., Kjær J., Cohet C., Goossens M., Andersen M., Hallas J., Meijerink H., Ljung R., and Hviid A., 2023, Comparative effectiveness of heterologous third dose vaccine schedules against severe covid-19 during omicron predominance in Nordic countries: population based cohort analyses, BMJ, 382. https://doi.org/10.1136/bmj-2022-074325 PMid:37487623 PMCid:PMC10360027 Au W.Y., and Cheung P.P.H., 2022, Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis, BMJ, 377. https://doi.org/10.1136/bmj-2022-069989 PMid:35640925 PMCid:PMC9724446 Baden L., Sahly H., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S., Rouphael N., Creech C., Mcgettigan J., Kehtan S., Segall N., Solis J., Brosz A., Fierro C., Schwartz H., Neuzil K., Corey L., Gilbert P., Janes H., Follmann D., Marovich M., Mascola J., Polakowski L., Ledgerwood J., Graham B., Bennett H., Pajon R., Knightly C., Leav B., Deng W., Zhou H., Han S., Ivarsson M., Miller J., and Zaks T., 2021, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, New England Journal of Medicine, 384(5): 403-416. https://doi.org/10.1056/NEJMoa2035389 PMid:33378609 PMCid:PMC7787219 Chavda V., Soni S., Vora L., Soni S., Khadela A., and Ajabiya J., 2022, mRNA-based vaccines and therapeutics for COVID-19 and future pandemics, Vaccines, 10(12): 2150. https://doi.org/10.3390/vaccines10122150 PMid:36560560 PMCid:PMC9785933 Cheng H., Peng Z., Si S., Alifu X., Zhou H., Chi P., Yan Z., Mo M., and Yu Y., 2022, Immunogenicity and safety of homologous and heterologous prime-boost immunization with COVID-19 vaccine: systematic review and meta-analysis, Vaccines, 10(5): 798. https://doi.org/10.3390/vaccines10050798 PMid:35632554 PMCid:PMC9142990 Choi A., Koch M., Wu K., Chu L., Ma L., Hill A., Nunna N., Huang W., Oestreicher J., Colpitts T., Bennett H., Legault H., Paila Y., Nestorova B., Ding B., Montefiori D., Pajon R., Miller J., Leav B., Carfi A., McPhee R., and Edwards D.K., 2021, Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis, Nature Medicine, 27(11): 2025-2031. https://doi.org/10.1038/s41591-021-01527-y PMid:34526698 PMCid:PMC8604720 Creech C., Anderson E., Berthaud V., Yildirim I., Atz A., Baez I., Finkelstein D., Pickrell P., Kirstein J., Yut C., Blair R., Clifford R., Dunn M., Campbell J., Montefiori D., Tomassini J., Zhao X., Deng W., Zhou H., Schrempp D., Hautzinger K., Girard B., Slobod K., McPhee R., Pajon R., Das R., Miller J., and Ghamloush S., 2022, Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age, New England Journal of Medicine, 386(21): 2011-2023. https://doi.org/10.1056/NEJMoa2203315 PMid:35544369 PMCid:PMC9127699 Das R., Hyer R., Burton P., Miller J., and Kuter B.J., 2023, Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape, Human Vaccines and Immunotherapeutics, 19(1): 2153532. https://doi.org/10.1080/21645515.2022.2153532 PMid:36629006 PMCid:PMC9980456 Du Y., Chen L., and Shi Y., 2022, Safety, immunogenicity, and efficacy of COVID-19 vaccines in adolescents, children, and infants: a systematic review and meta-analysis, Frontiers in Public Health, 10: 829176. https://doi.org/10.3389/fpubh.2022.829176 PMid:35493393 PMCid:PMC9046659 Feng P., Gu D.N., and Wang Y.F., 2024, Analysis of improvements to the Chickenpox vaccine and the development of new vaccines, Journal of Vaccine Research, 14(1): 1-9. https://doi.org/10.5376/jvr.2024.14.0001 Furer V., Eviatar T., Zisman D., Peleg H., Paran D., Levartovsky D., Zisapel M., Elalouf O., Kaufman I., Meidan R., Broyde A., Polachek A., Wollman J., Litinsky I., Meridor K., Nochomovitz H., Silberman A., Rosenberg D., Feld J., Haddad A., Gazzit T., Elias M., Higazi N., Kharouf F., Shefer G., Sharon O., Pel S., Nevo S., and Elkayam O., 2021, Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study, Annals of the Rheumatic Diseases, 80(10): 1330-1338. https://doi.org/10.1136/annrheumdis-2021-220647 PMid:34127481
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==